Skip to main content
Home > Week in Review > Clinical Results

Chronological Index of : Clinical Results

 Current Issue
  • AeroVanc: Phase II data

    Savara Pharmaceuticals, Austin, Texas Product: AeroVanc (SAV005) Business: Infectious Molecular target: NA Description: Inhaled dry powder formulation of vancomycin in a capsule-based inhaler Indication: Treat …

    Published on 3/2/2015
  • ALKS 7106: Development discontinued

    Alkermes plc(NASDAQ:ALKS), Dublin, Ireland Product: ALKS 7106 Business: Neurology Molecular target: NA Description: Oral small molecule opioid analgesic Indication: Treat pain Endpoint: Safety and pharmacokinetics …

    Published on 3/2/2015
  • AllerT: Phase IIb data

    Anergis S.A., Epalinges, Switzerland Product: AllerT Business: Inflammation Molecular target: NA Description: Birch pollen allergy vaccine containing contiguous overlapping peptides (COP) derived from birch pollen …

    Published on 3/2/2015
  • Ampion: Phase II data

    Ampio Pharmaceuticals Inc.(NYSE-M:AMPE), Englewood, Colo. Product: Ampion Business: Autoimmune Molecular target: NMDA receptor; Serotonin (5-HT2C) receptor Description: A cyclic aspartate-alanine dipeptide cleaved from …

    Published on 3/2/2015
  • Arhalofenate: Phase IIb data

    CymaBay Therapeutics Inc.(NASDAQ:CBAY), Newark, Calif. Product: Arhalofenate (MBX-102) Business: Endocrine/Metabolic Molecular target: Solute carrier family 22 organic anion urate transporter member 12 (SLC22A12) (URAT1…

    Published on 3/2/2015
  • Astragraf XL tacrolimus: Phase IIIb data

    Astellas Pharma Inc.(Tokyo:4503), Tokyo, Japan Product: Astragraf XL tacrolimus (Advagraf - EU, Graceptor) (FK506 MR) Business: Transplant Molecular target: FK506 binding protein (macrophilin-12) Description: Once-daily…

    Published on 3/2/2015
  • Astragraf XL tacrolimus transplant data

    Astellas Pharma Inc.(Tokyo:4503), Tokyo, Japan Product: Astragraf XL tacrolimus (Advagraf - EU, Graceptor) (FK506 MR) Business: Transplant Molecular target: FK506 binding protein (macrophilin-12) Description: Once-daily…

    Published on 3/2/2015
  • Baricitinib: Phase III data

    Incyte Corp.(NASDAQ:INCY), Wilmington, Del. Eli Lilly and Co.(NYSE:LLY), Indianapolis, Ind. Product: Baricitinib (LY3009104) (formerly INCB28050) Business: Autoimmune Molecular target: Janus kinase-2 (JAK-2); Janus …

    Published on 3/2/2015
  • Bryostatin-1: Phase IIa data

    Neurotrope Inc.(OTCQB:NTRP), Newark, N.J. Product: Bryostatin-1 Business: Neurology Molecular target: Protein kinase C (PKC) epsilon (PKCE) Description: Protein kinase C (PKC) epsilon (PKCE) activator Indication: Treat …

    Published on 3/2/2015
  • Eribulin mesylate: Phase III data

    Eisai Co. Ltd.(Tokyo:4523), Tokyo, Japan Product: Eribulin mesylate (Halaven) (E7389) Business: Cancer Molecular target: Tubulin polymerase Description: Synthetic analog of halichondrin B Indication: Treat soft tissue …

    Published on 3/2/2015
  • Hemangeol propranolol: Additional Phase II/III data

    Laboratoires Pierre Fabre S.A., Castres, France Maruho Co. Ltd., Osaka, Japan Product: Hemangeol propranolol (Hemangiol - EU) Business: Cancer Molecular target: Adrenergic receptor beta (ADRB) Description: Pediatric …

    Published on 3/2/2015
  • Maribavir: Additional Phase II data

    Shire plc(LSE:SHP; NASDAQ:SHPG), Dublin, Ireland GlaxoSmithKline plc(LSE:GSK; NYSE:GSK), London, U.K. Product: Maribavir (SHP620) Business: Infectious Molecular target: Not available Description: Oral …

    Published on 3/2/2015
  • OncoCEE-BR diagnostic data

    Biocept Inc.(NASDAQ:BIOC), San Diego, Calif. Product: OncoCEE-BR Business: Diagnostic Molecular target: NA Description: Diagnostic to detect circulating tumor cells (CTC) in the peripheral blood followed by genetic …

    Published on 3/2/2015
  • ONO-5163: Phase III data

    Amgen Inc.(NASDAQ:AMGN), Thousand Oaks, Calif. Ono Pharmaceutical Co. Ltd.(Tokyo:4528), Osaka, Japan Product: ONO-5163, AMG 416 (formerly Velcalcetide, KAI-4169) Business: Endocrine/Metabolic Molecular target: Calcium …

    Published on 3/2/2015
  • PerioPatch: Phase II data

    Izun Pharmaceuticals Corp., New York, N.Y. Product: PerioPatch Business: Dental Molecular target: NA Description: Topical transmucosal patch to absorb inflammatory exudates including gingival crevicular fluid (GCF) …

    Published on 3/2/2015
  • QuickShot Testosterone: Phase III data

    Antares Pharma Inc.(NASDAQ:ATRS), Ewing, N.J. Product: QuickShot Testosterone (QS T) Business: Endocrine/Metabolic Molecular target: Androgen receptor Description: Self-injectable formulation of testosterone enanthate …

    Published on 3/2/2015
  • Recombinant LP2086: Phase II data

    Pfizer Inc.(NYSE:PFE), New York, N.Y. Product: Recombinant LP2086, Trumenba (rLP2086, PF-5212366, PF-05212366) Business: Infectious Molecular target: NA Description: Bivalent meningococcal B vaccine targeting LP2086 (…

    Published on 3/2/2015
  • RI-002: Additional Phase III data

    ADMA Biologics Inc.(NASDAQ:ADMA), Ramsey, N.J. Product: RI-002 Business: Autoimmune Molecular target: NA Description: Human plasma-derived, polyclonal, IV immunoglobulin (IVIG) that has standardized high levels of …

    Published on 3/2/2015
  • Rilimogene galvacirepvec: Additional Phase I data

    Bavarian Nordic A/S(CSE:BAVA), Kvistgaard, Denmark Product: Rilimogene galvacirepvec (ProstVac) Business: Cancer Molecular target: Not available Description: Vaccine targeting PSA that also contains a Tricom triad of …

    Published on 3/2/2015
  • Sacituzumab govitecan: Additional Phase I/II data

    Immunomedics Inc.(NASDAQ:IMMU), Morris Plains, N.J. Product: Sacituzumab govitecan (hRS7-SN-38) (IMMU-132) Business: Cancer Molecular target: Epithelial glycoprotein-1 (EGP-1) Description: Humanized antibody against …

    Published on 3/2/2015
  • Sipuleucel-T: Phase II data

    Dendreon Corp.(Pink:DNDNQ), Seattle, Wash. Product: Sipuleucel-T Business: Cancer Molecular target: Not applicable Description: Autologous dendritic cells loaded with a fusion protein of prostatic acid phosphatase and …

    Published on 3/2/2015
  • Spiriva Respimat tiotropium bromide: Phase III data

    Boehringer Ingelheim GmbH, Ingelheim, Germany Product: Spiriva Respimat tiotropium bromide Business: Inflammation Molecular target: Muscarinic acetylcholine receptor M3 (CHRM3) (HM3) Description: Once-daily inhaled …

    Published on 3/2/2015
  • TD139: Phase Ib data

    Galecto Biotech AB, Copenhagen, Denmark Product: TD139 Business: Pulmonary Molecular target: Galectin-3 (LGALS3) Description: Galectin-3 (LGALS3) inhibitor Indication: Treat idiopathic pulmonary fibrosis (IPF) Endpoint:…

    Published on 3/2/2015
  • TEV-48125: Phase IIb data

    Teva Pharmaceutical Industries Ltd.(NYSE:TEVA), Petah Tikva, Israel Pfizer Inc.(NYSE:PFE), New York, N.Y. Product: TEV-48125 (formerly RN-307, LBR-101) Business: Neurology Molecular target: Calcitonin gene-related …

    Published on 3/2/2015
  • ThermoDox heat-activated liposome: Additional Phase III data

    Celsion Corp.(NASDAQ:CLSN), Lawrenceville, N.J. Yakult Honsha Co. Ltd.(Tokyo:2267), Tokyo, Japan Zhejiang Hisun Pharmaceutical Co. Ltd.(Shanghai:600267), Taizhou City, China Product: ThermoDox heat-activated liposome …

    Published on 3/2/2015

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993